Literature DB >> 28668565

M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.

Yasuko Hatta1, David Boltz2, Sally Sarawar3, Yoshihiro Kawaoka4, Gabriele Neumann5, Pamuk Bilsel6.   

Abstract

The emergence of highly pathogenic avian influenza H5N1 viruses has heightened global concern about the threat posed by pandemic influenza. To address the need for a highly effective universal influenza vaccine, we developed a novel M2-deficient single replication (M2SR) influenza vaccine virus and previously reported that it provided strong heterosubtypic protection against seasonal influenza viruses in mice. In the current study, we assessed M2SR induced protection against H5N1 influenza in mice and ferrets. Mice were intranasally inoculated with M2SR viruses containing the HA and NA from A/Vietnam/1203/2004 (M2SR H5N1) or A/California/07/2009 (M2SR H1N1). All M2SR vaccinated mice survived lethal challenge with influenza A/Vietnam/1203/2004 (H5N1), whereas 40% of mice vaccinated with recombinant H5 HA and none of the naïve controls survived. M2SR H5N1 provided sterile immunity, whereas low levels of virus were detected in the lungs of some M2SR H1N1 vaccinated mice. In contrast, recombinant H5 HA vaccinated mice and naïve controls showed systemic infection. M2SR H5N1 induced strong serum and mucosal antibody responses (IgG and IgA classes) against H5 HA, with high hemagglutination inhibition (HAI) titers. In contrast, while M2SR H1N1 elicited cross-reactive antibodies recognizing the H5 HA2 stalk region or the neuraminidase, no HAI activity against H5N1 virus was detected after M2SR H1N1 immunization. Both M2SR H5N1 and H1N1 also protected ferrets against lethal challenge with A/Vietnam/1203/2004. A prime-boost regimen provided optimal protection with no virus detected in the respiratory tract or brain after challenge. As in the mouse model, only the M2SR H5N1 vaccine induced HAI antibodies against the challenge virus in ferrets, while the M2SR H1N1 was able to provide protection without the induction of HAI antibodies. In summary, effective protection against highly pathogenic H5N1 influenza virus was provided by both homologous H5N1 M2SR and heterologous H1N1 M2SR demonstrating the cross-protective attributes of the M2SR platform.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HA2 stalk region; Hemagglutination inhibition; Heterosubtypic immunity; Highly pathogenic H5N1 avian influenza; Long-lasting protection; M2-deficient; Neuraminidase; Single replication; Sterilizing immunity; Universal influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28668565      PMCID: PMC5587242          DOI: 10.1016/j.vaccine.2017.06.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

2.  Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

Authors:  K Y Yuen; P K Chan; M Peiris; D N Tsang; T L Que; K F Shortridge; P T Cheung; W K To; E T Ho; R Sung; A F Cheng
Journal:  Lancet       Date:  1998-02-14       Impact factor: 79.321

3.  Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.

Authors:  J M Katz; W Lim; C B Bridges; T Rowe; J Hu-Primmer; X Lu; R A Abernathy; M Clarke; L Conn; H Kwong; M Lee; G Au; Y Y Ho; K H Mak; N J Cox; K Fukuda
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Takeshi Noda; Maki Kiso; Junko Maeda; Shinji Watanabe; Yukiko Muramoto; Ken Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Authors:  Kutubuddin Mahmood; Rick A Bright; Nutan Mytle; Donald M Carter; Corey J Crevar; Jenna E Achenbach; Penny M Heaton; Terrence M Tumpey; Ted M Ross
Journal:  Vaccine       Date:  2008-08-14       Impact factor: 3.641

6.  Characterization of avian H5N1 influenza viruses from poultry in Hong Kong.

Authors:  K F Shortridge; N N Zhou; Y Guan; P Gao; T Ito; Y Kawaoka; S Kodihalli; S Krauss; D Markwell; K G Murti; M Norwood; D Senne; L Sims; A Takada; R G Webster
Journal:  Virology       Date:  1998-12-20       Impact factor: 3.616

7.  Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.

Authors:  Kristien Van Reeth; Debby Braeckmans; Eric Cox; Steven Van Borm; Thierry van den Berg; Bruno Goddeeris; Annebel De Vleeschauwer
Journal:  Vaccine       Date:  2009-10-23       Impact factor: 3.641

8.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

9.  Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge.

Authors:  Mariana Baz; Kobporn Boonnak; Myeisha Paskel; Celia Santos; Timothy Powell; Alain Townsend; Kanta Subbarao
Journal:  mBio       Date:  2015-10-20       Impact factor: 7.867

10.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.

Authors:  Julie E Ledgerwood; Chih-Jen Wei; Zonghui Hu; Ingelise J Gordon; Mary E Enama; Cynthia S Hendel; Patrick M McTamney; Melissa B Pearce; Hadi M Yassine; Jeffrey C Boyington; Robert Bailer; Terrence M Tumpey; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  Lancet Infect Dis       Date:  2011-10-03       Impact factor: 25.071

View more
  13 in total

Review 1.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

2.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

3.  Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.

Authors:  Yasuko Hatta; David Boltz; Sally Sarawar; Yoshihiro Kawaoka; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2018-07-13       Impact factor: 3.641

4.  Comparison of Heterosubtypic Protection in Ferrets and Pigs Induced by a Single-Cycle Influenza Vaccine.

Authors:  Barbara Holzer; Sophie B Morgan; Yumi Matsuoka; Matthew Edmans; Francisco J Salguero; Helen Everett; Sharon M Brookes; Emily Porter; Ronan MacLoughlin; Bryan Charleston; Kanta Subbarao; Alain Townsend; Elma Tchilian
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

Review 5.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

Review 6.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

Review 7.  The Intersection of Age and Influenza Severity: Utility of Ferrets for Dissecting the Age-Dependent Immune Responses and Relevance to Age-Specific Vaccine Development.

Authors:  Melissa Rioux; Magen E Francis; Cynthia L Swan; Anni Ge; Andrea Kroeker; Alyson A Kelvin
Journal:  Viruses       Date:  2021-04-15       Impact factor: 5.048

Review 8.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 9.  M2e-based universal influenza vaccines: a historical overview and new approaches to development.

Authors:  Daria Mezhenskaya; Irina Isakova-Sivak; Larisa Rudenko
Journal:  J Biomed Sci       Date:  2019-10-19       Impact factor: 8.410

Review 10.  Next-generation influenza vaccines: opportunities and challenges.

Authors:  Chih-Jen Wei; Michelle C Crank; John Shiver; Barney S Graham; John R Mascola; Gary J Nabel
Journal:  Nat Rev Drug Discov       Date:  2020-02-14       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.